The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies

OBJECTIVES: Ibrutinib is active in anti–myelin-associated glycoprotein (MAG) polyneuropathy with MYD88(L265P) mutation; however, its efficacy is likely to be low in MYD88 wild-type patients. Venetoclax, an oral inhibitor of BCL2, in combination with rituximab is highly active in ibrutinib-resistant...

Descripción completa

Detalles Bibliográficos
Autores principales: Briani, Chiara, Visentin, Andrea, Castellani, Francesca, Cacciavillani, Mario, Trentin, Livio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Clinical/Scientific Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128027/
https://www.ncbi.nlm.nih.gov/pubmed/35577568
http://dx.doi.org/10.1212/NXI.0000000000001181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128027/
https://www.ncbi.nlm.nih.gov/pubmed/35577568
http://dx.doi.org/10.1212/NXI.0000000000001181

Ejemplares similares